/
EVGN
$0.43+$0.04 (+10.93%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.7M
12M shares
52-week range
$0.37 – $1.50
5% from low
Exchange
NASDAQ
CS
Borrow rate
13.28%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-33.77
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $753.0K | $1.0M | $930.0K | $1.7M | $3.0M | $5.6M | $3.9M |
| Cost of revenue | $1.5M | $334.0K | $574.0K | $767.0K | $909.0K | $1.5M | $2.4M | $4.1M |
| Gross profit | $295.0K | $419.0K | $466.0K | $163.0K | $766.0K | $1.5M | $3.2M | −$241.0K |
| Gross margin | 16.9% | 55.6% | 44.8% | 17.5% | 45.7% | 50.0% | 57.3% | -6.3% |
| R&D | $14.7M | $15.8M | $17.3M | $21.1M | $20.8M | $16.2M | $12.5M | $8.0M |
| Operating income | −$20.0M | −$21.2M | −$24.8M | −$31.0M | −$26.9M | −$22.2M | −$18.8M | −$14.0M |
| EBITDA | −$18.8M | −$16.0M | −$23.2M | −$27.9M | −$27.0M | −$20.5M | −$13.4M | −$12.2M |
| Net income | −$20.8M | −$18.1M | −$23.4M | −$27.8M | −$26.6M | −$23.9M | −$16.5M | −$8.5M |
| Net margin | -1188.2% | -2405.3% | -2247.5% | -2988.5% | -1590.3% | -800.8% | -295.6% | -220.2% |
| EPS (diluted) | -0.81 | -0.70 | -0.64 | -0.68 | -6.46 | -5.23 | -2.89 | -1.08 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-1.70 | $-1.70–$-1.70 | 1 |
| 2027 | $3M | $-0.80 | $-0.80–$-0.80 | 1 |
| 2028 | $5M | $-0.55 | $-0.55–$-0.55 | 1 |
| 2029 | $8M | $-0.40 | $-0.40–$-0.40 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
EVOGENE LTD.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
www.evogene.com- Employees
- 52
- IPO / List date
- Mar 5, 2008
Held by traders on TradeandTell
No one on the platform currently holds EVGN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in EVGN as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-07-25 | 1-for-10reverse |
| 2013-11-18 | 1-for-2reverse |
Recent trades on TradeandTell
No one on the platform has traded EVGN yet.
